Cargando…
Novel anti-melanoma treatment: focus on immunotherapy
Melanoma is an intractable cancer that is aggressive, lethal, and metastatic. The prognosis of advanced melanoma is very poor because it is insensitive to chemotherapy and radiotherapy. The incidence of melanoma has been ascending stably for years worldwide, accompanied by increasing mortality. New...
Autores principales: | Hao, Meng-Ze, Zhou, Wen-Ya, Du, Xiao-Ling, Chen, Ke-Xin, Wang, Guo-Wen, Yang, Yun, Yang, Ji-Long |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sun Yat-sen University Cancer Center
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190435/ https://www.ncbi.nlm.nih.gov/pubmed/25189718 http://dx.doi.org/10.5732/cjc.014.10118 |
Ejemplares similares
-
Editorial of special focus on melanoma immunotherapy
por: Rossi, Ernesto
Publicado: (2022) -
Novel Anti-Melanoma Immunotherapies: Disarming Tumor Escape Mechanisms
por: Sapoznik, Sivan, et al.
Publicado: (2012) -
A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma
por: Guo, Weinan, et al.
Publicado: (2020) -
HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma
por: Huang, Fu-xue, et al.
Publicado: (2022) -
A real‐world study of adjuvant anti‐PD ‐1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations
por: Sun, Wei, et al.
Publicado: (2023)